Attachment and Fusion Inhibitors Potently Prevent Dendritic Cell-Driven HIV Infection

Center for Biomedical Research, Population Council, New York, NY 10065, USA.
JAIDS Journal of Acquired Immune Deficiency Syndromes (Impact Factor: 4.56). 11/2010; 56(3):204-12. DOI: 10.1097/QAI.0b013e3181ff2aa5
Source: PubMed


Dendritic cells (DCs) efficiently transfer captured (trans) or de novo-produced (cis) virus to CD4 T cells. Using monocyte-derived DCs, we evaluated entry inhibitors targeting HIV envelope (BMS-C, T-1249) or CCR5 (CMPD167) for their potency to prevent DC infection, DC-driven infection in T cells in trans and cis, and direct infection of DC-T-cell mixtures. Immature DC-T-cell cultures with distinct mechanisms of viral transfer yielded similar levels of infection and produced more proviral DNA compared with matched mature DC-T-cell cultures or infected immature DCs. Although all compounds completely blocked HIV replication, 16 times more of each inhibitor (250 vs 15.6 nM) was required to prevent low-level infection of DCs compared with the productive DC-T-cell cocultures. Across all cell systems tested, BMS-C blocked infection most potently. BMS-C was significantly more effective than CMPD167 at preventing DC infection. In fact, low doses of CMPD167 significantly enhanced DC infection. Elevated levels of CCL4 were observed when immature DCs were cultured with CMPD167. Viral entry inhibitors did not interfere with Candida albicans-specific DC cytokine/chemokine responses. These findings indicate that an envelope-binding small molecule is a promising tool for topical microbicide design to prevent the infection of early targets needed to establish and disseminate HIV infection.

Full-text preview

Available from:
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dendritic cells and their subsets are among the very first immune cells to tackle incoming pathogens and initiate innate and adaptive immune responses. During the past year, some studies investigating the early events occurring at mucosal sites, upon HIV infection, reinforced our view that the virus has evolved subtle strategies to hijack key cellular components in dendritic cells, thus leading to viral acquisition and dissemination while dampening or delaying antiviral responses. In this review, we will detail recent research aimed at investigating the involvement of different dendritic cell subtypes on HIV transmission at mucosal sites, the events and cellular factors in dendritic cell guiding HIV trafficking, and polarization at the virological synapse. Furthermore, we will link some of these basic findings with current and novel therapeutic and prophylactic strategies targeting the early events of mucosal HIV transmission. It is becoming evident that a better characterization of the early events of HIV transmission and the involvement of dendritic cell subtypes in this process would contribute to strengthen our efforts to improve the current therapeutic and prophylactic strategies.
    Current opinion in HIV and AIDS 09/2011; 6(5):391-7. DOI:10.1097/COH.0b013e328349b0a0 · 4.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The idea for microbicides to prevent the transmission of sexually transmitted infections came from a discovery in the 1980s that over-the-counter spermicides showed antiviral activity in vitro. Since the advent of the HIV epidemic, microbicides have been tested as a possible tool for HIV prevention. The field of HIV microbicides has expanded to include five classes of mechanisms: surfactants, buffering agents, viral entry inhibitors, reverse transcriptase inhibitors and agents with an unknown mechanism. The most successful class to date has been the reverse transcriptase inhibitors, specifically tenofovir gel. Despite numerous setbacks in clinical studies (such as issues of adherence, interference with vaginal defenses and insufficient sample size to determine efficacy), the future of microbicide research is promising, with numerous agents in ongoing clinical studies. Copyright © 2011 Prous Science, S.A.U. or its licensors. All rights reserved.
    Drugs of the Future 12/2011; 36(12):909. DOI:10.1358/dof.2011.036.12.1708828 · 0.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Topical blockade of the gp41 fusogenic protein of HIV-1 is one possible strategy by which microbicides could prevent HIV transmission, working early against infection, by inhibiting viral entry into host cells. In this study, we examined the potential of gp41 fusion inhibitors (FIs) as candidate anti-HIV microbicides. Preclinical evaluation of four FIs, C34, T20, T1249, and L'644, was performed using cellular and ex vivo genital and colorectal tissue explant models. Increased and sustained activity was detected for L'644, a cholesterol-derivatized version of C34, relative to the other FIs. The higher potency of L'644 was further increased with sustained exposure of cells or tissue to the compound. The activity of L'644 was not affected by biological fluids, and the compound was still active when tissue explants were treated after viral exposure. L'644 was also more active than other FIs against a viral escape mutant resistant to reverse transcriptase inhibitors (RTIs), demonstrating the potential of L'644 to be included as part of a multiactive antiretroviral (ARV) combination-based microbicide. These data support the further development of L'644 for microbicide application.
    Antimicrobial Agents and Chemotherapy 02/2012; 56(5):2347-56. DOI:10.1128/AAC.06108-11 · 4.48 Impact Factor
Show more